Phosphorylation of ERK1/2 in Patients With Parkinson's Disease
NCT ID: NCT01142739
Last Updated: 2012-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2010-06-30
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will be performed in dyskinetic levodopa-treated patients and non-Parkinson's Disease controls. Blood sampling "off" and "on" levodopa treatment (1 hour post-dose), as well as clinical data collection will be done during a scheduled pre-op work-up (deep brain stimulation). Subsequently, suspended lymphocytes from blood samples will be immunolabelled using an anti-pERK antibody and mean fluorescence intensity and percent of labelled lymphocytes will be assessed by flow cytometry. Additionally, plasma and urine samples will be collected "on" et "off" for dosage of dopamine. The motor effect of levodopa will be assessed through UPRSIII rating scale and eye movement (saccades) speed by non-invasive oculometric recordings.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parkinson's Disease patient
levodopa-treated parkinson's disease (PD) patients
Clinical variables
Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
Clinical variables
Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
Non Parkinson's disease controls
Non Parkinson's disease controls
Clinical variables
Demography, Biological variables.
Clinical variables
Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical variables
Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
Clinical variables
Demography, Biological variables.
Clinical variables
Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-demented patients (DSM IV) who are able to give their informed consent and who are affiliated to the social security.
* Controls: Subjects without known neurological disorder, non-demented, able to give their informed consent and affiliated to the social security.
Exclusion Criteria
* Previous or current cancer or malignant haemopathy.
* Known auto-immune disease.
* Anti-neoplastic or immuno-modulator treatment (particularly corticosteroids). Immuno-deficient subjects.
* Acute viral infection (within 2 weeks after resolving). Statin drug intake. Demented subject (DSMIV).
* Controls: Same criteria as above plus any neurological disease.
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université Victor Segalen Bordeaux 2
OTHER
University Hospital, Bordeaux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nathalie DAMON-PERRIERE, Dr.
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Bordeaux
Geneviève CHENE, Pr
Role: STUDY_CHAIR
University Hospital, Bordeaux
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Bordeaux Hôpital Haut Lévêque
Pessac, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUBX 2009/20
Identifier Type: -
Identifier Source: org_study_id